(UroToday.com) Dr. Wolfgang Beck, University of North Carolina, Chapel Hill, North Carolina, USA presented “Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma.”  The investigators performed post hoc analysis on IMvigor210 data and identified an age cutoff point of 72 years, with older patients achieving a relatively better response than younger patients.  Dr. Beck et al. then included age among other validated clinical and genomic predictors to create a model for immune checkpoint blockade response in advanced disease.  These data have implications on the selection of first-line therapy in de novo advanced disease in elderly patient populations.